cAMP response element modulator α expression in patients with systemic lupus erythematosus

Lupus

Volumn 15, Issue 12, 2006, Pages 840-844

  Kyttaris, V C ^a,b,c   Wang, Y ^a   Juang, Y T ^a,b   Weinstein, A ^c   Tsokos, George C ^a,b,d  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b Uniformed Services University of the Health Sciences   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d WRAIR   (United States)

Author keywords

Corticosteroids; CREM; Lupus; T cells; Transcription factors

Indexed keywords

CORTICOSTEROID DERIVATIVE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MESSENGER RNA; NUCLEIC ACID BINDING PROTEIN; PROTEIN CYCLIC AMP RESPONSIVE ELEMENT MODULATOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG MEGADOSE; FEMALE; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADRENAL CORTEX HORMONES; ADULT; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT MODULATOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; FEMALE; GENE EXPRESSION; HUMANS; INTERLEUKIN-2; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 33845994433     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306069985     Document Type: Article

References (15)

1. Tsokos GC, Nambiar MP, Tenbrock K, Juang YT. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol 2003; 24: 259-263.
2. Linker-Israeli M, Bakke AC, Kitridou RC et al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 1983; 130: 2651-2655.
3. Iliopoulos AG, Tsokos GC. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 1996; 25: 318.
4. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4: 665-674.
5. Liu MF, Wang CR, Fung LL, Wu CR. Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 2004; 59: 198-202.
6. Tsokos GC, Kammer GM. Molecular aberrations in human systemic lupus erythematosus. Mol Med Today 2000; 6: 418.
7. Tsokos GC, Boumpas DT. Systemic lupus erythematosus. In Molecular pathology of autoimmunity. Gordon and Breach, Harwood Academic Publishers, 2001; 255.
8. Jain J, Loh C, Rao A. Transcriptional regulation of the IL-2 gene. Curr Opin Immunol 1995; 7: 333-342.
9. Solomou EE, Juang YT, Gourley MF, Kammer GM, Tsokos GC. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol 2001; 166: 4216-4222.
10. Kyttaris VC, Juang YT, Tenbrock K, Weinstein A, Tsokos GC. Cyclic adenosine 5′-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J Immunol 2004; 173: 3557-3563.
11. Hochberg M. Updating the American College of Rheumatology Revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
12. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. Arthritis Rheum 1992; 6: 630.
13. Bustin SA. Absolute quantification using real-time reverse transcription polymerasechain reaction assays. J Molecular Endocrinology 2000; 25: 169-193.
14. Vacca A, Felli MP, Farina AR et al. Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 1992; 175: 637-646.
15. Juang YT, Wang Y, Solomou EE et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005; 115: 996-1005.